Tom Powles: More evidence that PD(L)1 re-challenge should be avoided in renal cancer

Tom Powles posted on X/Twitter:

“More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivolumab showed no increased efficacy compared to  Tivozanib alone in PD(L)1 pretreated RCC patients. The decreased Tivozanib dose in study arm requires consideration. This has implications post adjuvant pembrolizumab“

For more information.
Source: Tom Powles/X

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.